CoChat

Engineering immunomodulatory biomaterials for type 1 diabetes

Open access
Stabler, C. L., Li, Y., Stewart, J. M., Keselowsky, B. G. · 2019 · Nature Reviews Materials
Cited by 125

The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.

Abstract

A cure for type 1 diabetes (T1D) would help millions of people worldwide but remains elusive to date. Tolerogenic vaccines and β-cell replacement therapy are complementary therapies that seek to address aberrant T1D autoimmune attack and subsequent β-cell loss. However, both approaches require some form of systemic immunosuppression, imparting risks to the patient. Biomaterials-based tools enable localized and targeted immunomodulation, and biomaterial properties can be designed and combined with immunomodulatory agents to locally instruct specific immune responses. In this Review, we discuss immunomodulatory biomaterial platforms for the development of T1D tolerogenic vaccines and β-cell replacement devices. We investigate nanoparticles and microparticles for the delivery of tolerogenic agents and autoantigens and as artificial antigen-presenting cells, and we highlight how bulk biomaterials can be used to provide immune tolerance. We examine biomaterials for drug delivery and as immuno-isolation devices for cell therapy and islet transplantation and explore synergies with other fields for the development of new T1D treatment strategies.Type 1 diabetes is an autoimmune disease that causes the destruction of pancreatic β-cells, which results in an insulin deficiency. In this Review, the authors discuss immunomodulatory biomaterials for β-cell replacement and for the induction of tolerogenic immune responses to prevent, delay or reverse the disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41578-019-0112-5

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 45 references

Cited by

See all 125

Metadata

Authors
Stabler, C. L., Li, Y., Stewart, J. M., & Keselowsky, B. G.
Venue
Nature Reviews Materials
Published
2019-05-17
Volume
4
Issue
6
Pages
429-450
ISSN
2058-8437 (ISSN-L)
OpenAlex
W2945971202
Cited by
125
References
45
FWCI
2.52
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Engineering immunomodulatory biomaterials for type 1 diabetes. https://app.cochat.ai/papers/10.1038/s41578-019-0112-5
The paper
Stabler, C. L., Li, Y., Stewart, J. M., & Keselowsky, B. G. (2019). Engineering immunomodulatory biomaterials for type 1 diabetes. Nature Reviews Materials. https://doi.org/10.1038/s41578-019-0112-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.